Atossa Therapeutics (NASDAQ:ATOS) Announces Earnings Results

Atossa Therapeutics (NASDAQ:ATOS) issued its quarterly earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01, Zacks reports.

Atossa Therapeutics Trading Down 0.2 %

ATOS stock traded down $0.00 during trading on Tuesday, reaching $0.75. The stock had a trading volume of 71,899 shares, compared to its average volume of 1,017,699. The firm has a fifty day moving average price of $0.80 and a 200 day moving average price of $1.12. The company has a market capitalization of $93.97 million, a P/E ratio of -3.40 and a beta of 1.20. Atossa Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.31.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE raised its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 111,475 shares of the company’s stock after buying an additional 37,809 shares during the quarter. Bank of America Corp DE owned about 0.09% of Atossa Therapeutics worth $105,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Atossa Therapeutics in a research report on Wednesday, March 12th. Ascendiant Capital Markets increased their price objective on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.